Perennial allergic rhinitis

This early-stage trial tests a new biologic drug called ASP2390, given as a skin injection, in 28 adults with house dust mite allergies. The main goal is to check safety and how the immune system responds, not yet whether it works. If successful, it could lead to a new way to eas…

This phase 3 study tests lebrikizumab, an injectable drug, in 450 adults with perennial allergic rhinitis (year-round allergies). The goal is to see if it reduces nasal symptoms like congestion and sneezing compared to a placebo. Participants will be followed for up to 29.5 month…

This study tests a new injection called LP-003 in 6 teenagers aged 12 to 18 who have allergies like hay fever, asthma, or eczema. The main goal is to check if the drug is safe and how the body processes it. This is an early-stage trial, so it focuses on safety and drug levels rat…

This study looks at how dupilumab changes the way the nose and blood respond to house dust mites in adults with allergic asthma. Participants will be exposed to dust mites in a special chamber and receive either dupilumab or a placebo. The goal is to understand the drug's effects…

This study looks at the bacteria living in the nose and sinuses of people with chronic sinusitis, allergies, and healthy individuals. By analyzing tissue samples from 285 participants, researchers hope to identify which bacteria are linked to long-term inflammation. The goal is t…